← Back to headlines
Exelixis Stock Falls After Disappointing Zanzalintinib Phase 3 Data
Exelixis shares dropped following the final analysis of its zanzalintinib phase 3 trial data, which reportedly disappointed investors.
22 Jun, 15:14 — 22 Jun, 15:14
Sources
Showing 1 of 1 sources
